Published in PLoS One on July 31, 2014
MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol (2011) 220.97
Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res (2003) 103.76
EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet (2000) 69.26
MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics (2004) 50.89
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol (2006) 10.21
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Replication of hepatitis C virus. Nat Rev Microbiol (2007) 8.31
Datamonkey 2010: a suite of phylogenetic analysis tools for evolutionary biology. Bioinformatics (2010) 6.14
Computing topological parameters of biological networks. Bioinformatics (2007) 5.36
Unravelling hepatitis C virus replication from genome to function. Nature (2005) 5.25
Evasion of intracellular host defence by hepatitis C virus. Nature (2005) 4.58
The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med (1998) 4.48
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology (2014) 4.15
Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology (2001) 3.80
Natural history of hepatitis C. Clin Liver Dis (2005) 3.34
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology (1997) 3.10
Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol (2007) 3.04
Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol (2000) 2.68
Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology (1994) 2.60
Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest (2008) 2.08
Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology (1998) 2.06
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (2012) 1.97
Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol (1999) 1.96
Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol (2001) 1.92
Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis (2000) 1.75
Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol (2001) 1.74
Viral hepatocarcinogenesis. Oncogene (2010) 1.73
The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol (2009) 1.67
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63
Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology (2000) 1.50
Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res (2003) 1.47
Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther (2005) 1.46
Severity of liver disease with different hepatitis C viral clones. Lancet (1991) 1.40
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol (2007) 1.38
Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology (1997) 1.24
An overview about hepatitis C: a devastating virus. Crit Rev Microbiol (2010) 1.23
Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev (2012) 1.22
A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res (2006) 1.19
Coordinated evolution of the hepatitis C virus. Proc Natl Acad Sci U S A (2008) 1.19
Hepatitis C virus RNA: dinucleotide frequencies and cleavage by RNase L. Virus Res (2007) 1.18
Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology (2007) 1.16
Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology (1996) 1.12
Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. J Med Virol (1994) 1.10
Distinct hepatitis C virus core and F protein quasispecies in tumoral and nontumoral hepatocytes isolated via microdissection. Hepatology (2007) 1.10
Hepatitis C virus and the immune system: a concise review. Rev Med Virol (2005) 1.08
A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. Virol J (2005) 1.06
Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol (2005) 1.04
Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS One (2008) 1.02
Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin Cancer Res (2009) 0.99
High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. Hepatology (2001) 0.97
T cell response in hepatitis C virus infection. J Clin Virol (2005) 0.96
Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. PLoS One (2010) 0.95
Hepatitis C virus genotypes, reactivity to recombinant immunoblot assay 2 antigens and liver disease. J Med Virol (1994) 0.93
Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy. J Virol (2011) 0.92
The oncogenic potential of hepatitis C virus NS5A sequence variants is associated with PKR regulation. J Interferon Cytokine Res (2005) 0.90
Characteristics of hepatitis C viral genome associated with disease progression. Hepatology (2000) 0.90
Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma. J Clin Microbiol (2002) 0.90
Lack of association between type of hepatitis C virus, serum load and severity of liver disease. J Viral Hepat (1996) 0.90
Investigation of the relative infectivity and pathogenicity of different hepatitis C virus genotypes in hemophiliacs. Blood (1996) 0.89
Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. J Med Virol (2011) 0.89
Comparative sequence analysis of the core- and NS5-region of hepatitis C virus from tumor and adjacent non-tumor tissue. J Med Virol (2001) 0.88
Making it happen: managed care considerations in vanquishing hepatitis C. Am J Manag Care (2007) 0.87
Nonstructural proteins 4A and 4B of hepatitis C virus transactivate the interleukin 8 promoter. Microbiol Immunol (2005) 0.87
Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1b. Am J Gastroenterol (1996) 0.87
Potentially curative treatment in patients with hepatocellular cancer--results from the liver cancer research network. Aliment Pharmacol Ther (2012) 0.86
Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan. Intervirology (2006) 0.86
Simeprevir: first global approval. Drugs (2013) 0.85
Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy. Intervirology (2012) 0.85
Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J Med Virol (2010) 0.85
Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics. Genome Med (2011) 0.84
Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. Hepatol Int (2011) 0.84
Hepatitis C virus (HCV) genotype 1b sequences from fifteen patients with hepatocellular carcinoma: the 'progression score' revisited. Hepatol Res (2001) 0.82
Pathogenesis of hepatocellular damage in chronic hepatitis C virus infection. Clin Liver Dis (1997) 0.82
Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy. PLoS One (2011) 0.81
Prevalence of wild-type in NS5A-PKR protein kinase binding domain in HCV-related hepatocellular carcinoma. J Hepatol (2002) 0.81
Coordinated evolution among hepatitis C virus genomic sites is coupled to host factors and resistance to interferon. In Silico Biol (2012) 0.80
Hepatitis C virus core protein and hepatitis activity are associated through transactivation of interleukin-8. J Infect Dis (2005) 0.79
Genome-wide networks of amino acid covariances are common among viruses. J Virol (2012) 0.78